Fig. 3
High-dose rIL-37 could not reverse T2DM induced by HFD and STZ. (A) rIL-37 at 100 ng/ml concentration decreased the fasting blood glucose level of experimental T2D effectively, but 1000 ng/ml rIL-37 did not. (B, C) rIL-37 at 100 ng/ml concentration improved glucose tolerance (IPGTT) and insulin tolerance (ITT) effectively in experimental T2D, but 1000 ng/ml rIL-37 did not. (D) The 100 ng/ml rIL-37 effectively reduced immunohistochemical staining of F4/80-positive cells in islets of experimental T2DM but 1000 ng/ml rIL-37 can not. (Scale bar = 50 μm). (E) Enhanced level of serum IL-37 in patients with T2DM compared with healthy controls. HC, healthy control; T2DM, type 2 diabetes mellitus. vs. WT-normal group, *P<0.05, **P<0.01, ***P<0.001; vs. WT-T2DM, &P<0.05; vs. IL-37 100 ng/ml, #P<0.05, ##P<0.01.
